Search Results for: covid-19
Articles
OSE Immunotherapeutics Announces Manufacturing Agreement With Cenexi July 1, 2021
OSE Immunotherapeutics and Cenexi recently announced the signature of an agreement whereby Cenexi will manufacture clinical batches of CoVepiT, OSE Immunotherapeutics'...Altimmune Announces Update on AdCOVID Phase 1 Clinical Trial July 1, 2021
Altimmune, Inc. recently provided an update on its AdCOVID investigational vaccine for the prevention of COVID-19. The company also provided...2021 Respiratory Drug Development eBook – The Three Cs Driving Respiratory Drug Delivery June 29, 2021
In this third annual Drug Development & Delivery Respiratory eBook, several companies discuss what they are currently working on to propel the respiratory sector.
Veru Announces the Presentation of a Phase 1b/2 Clinical Study Update for Sabizabulin June 29, 2021
Veru Inc. recently announced updated clinical results from the ongoing Phase 1b/2 clinical study of sabizabulin (VERU-111), an oral cytoskeleton...Onconova Therapeutics Provides Update on the Phase 1/2a Trial of Rigosertib-Nivolumab Combination in KRAS+ Non-Small Cell Lung Cancer June 29, 2021
Onconova Therapeutics, Inc. recently announced an update on the investigator-initiated Phase 1/2a trial of oral rigosertib plus nivolumab in advanced...Fulcrum Therapeutics Announces Results from ReDUX4 Trial With Losmapimod in Facioscapulohumeral Muscular Dystrophy Demonstrating Slowed Disease Progression & Improved Function June 29, 2021
Fulcrum Therapeutics, Inc. recently announced results from the company’s Phase 2b trial, ReDUX4, in people with facioscapulohumeral muscular dystrophy (FSHD). Results being presented with….
Onconova Therapeutics Announces Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Rigosertib Combined With Immune Checkpoint Blockade June 23, 2021
Onconova Therapeutics, Inc. recently announced the publication of a preclinical study in the journal Molecular Cancer. The study, titled Novel...BioNTech Announces First Patient Dosed in Phase 2 Clinical Trial of mRNA-Based BNT111 in Patients With Advanced Melanoma June 23, 2021
BioNTech SE recently announced the first patient has been treated in its BNT111 Phase 2 cancer vaccine trial (2020-002195-12; NCT04526899)....LexaGene Detects a Slow-Growing Bacterium at Least 36-Times Faster Than Conventional Methods With Potential to Increase Vaccine Safety & Supply June 16, 2021
LexaGene Holdings, Inc. recently announced it has successfully utilized the MiQLab System to detect the presence of a slow growing bacterium,...Hovione & iBET Announce Strategic Collaboration June 3, 2021
Hovione was a founding member of iBET in 1989 and has just re-joined the membership of the Instituto de Biologia...WEARABLE PLATFORM - Next-Generation Wearable Drug Delivery: Prefilled Devices Provide a Truly Patient-Centric Solution June 2, 2021
Mindy Katz says with increasingly positive expectations for the wearable device market to provide an intuitive and user-friendly drug delivery experience, her company continues to optimize its wearable platform solution, investigating new technologies and processes to improve the offerings for patients and providers.
SPECIAL FEATURE - Outsourcing Formulation Development & Manufacturing: Meeting Demand for Biologics & Specialty Drugs June 2, 2021
Contributor Cindy Dubin highlights the formulation development and manufacturing offerings from some of the leading CDMOs to address a myriad of challenges – from complex compounds to poor solubility to dual-release profiles.
DRUG DEVELOPMENT EXECUTIVE - Enteris BioPharma: How to Build a Preferred CDMO Partner June 1, 2021
Dr. Paul Shields, COO of Enteris BioPharma, discusses the changing face of the CDMO industry and how his company plans to leverage its newly expanded CDMO operations to take advantage of a variety of growth opportunities to build deeper partnerships.
GLOBAL REPORT - 2020 Global Drug Delivery & Formulation Report: Part 4, The Drug Delivery and Formulation Pipeline June 1, 2021
In part 4 of this 4-part series, PharmaCircle, in collaboration with Drug Development & Delivery, provides pipeline snapshots and comparisons for a number of parameters that are of most interest to drug delivery and formulation professionals – Disease Area, Molecule Type, and Delivery Route.
EXECUTIVE INTERVIEW - Poseida Therapeutics: Creating the Next Wave of Cell & Gene Therapies With the Capacity to Cure June 1, 2021
Eric M. Ostertag, MD, PhD, Chief Executive Officer of Poseida Therapeutics, discusses the company’s innovative approach to develop safer, more effective, accessible and affordable cell and gene therapies for patients.
Ginkgo Bioworks & Biogen Announce Collaboration & License Agreement to Develop Novel Gene Therapy Manufacturing Platform May 26, 2021
Ginkgo Bioworks and Biogen recently announced a gene therapy collaboration in which the companies aim to redefine the industry standard for manufacturing recombinant adeno-associated virus (AAV)-based vectors…..
Onconova Therapeutics Announces Initial Dosing of First Patient in US Phase 1 Clinical Trial May 26, 2021
Onconova Therapeutics, Inc. recently announced the first patient has been dosed in the US Phase 1 clinical trial of ON...The Discovery Labs Signs Foundational Lease With the University of Pennsylvania Gene Therapy Program as Anchor Tenant May 26, 2021
The Discovery Labs has recently signed a foundational lease with the University of Pennsylvania Gene Therapy Program (GTP), which will...Advicenne Receives Positive Feedback From US FDA on Pathway to Approval & Amended Phase 3 Study Protocol May 19, 2021
Advicenne recemtly announced the US FDA acceptance of the amended protocol of the company’s US-based Phase 3 pivotal trial of...BD to Build New Manufacturing Facility in Spain to Support Ongoing Strong Growth of Prefilled Drug Delivery Business May 19, 2021
BD (Becton, Dickinson and Company) recently announced will build a $200-million high-tech manufacturing facility in city of Zaragoza, located in...
